MX2023000804A - Peptidos para usarse en la promocion del transporte de glucosa. - Google Patents
Peptidos para usarse en la promocion del transporte de glucosa.Info
- Publication number
- MX2023000804A MX2023000804A MX2023000804A MX2023000804A MX2023000804A MX 2023000804 A MX2023000804 A MX 2023000804A MX 2023000804 A MX2023000804 A MX 2023000804A MX 2023000804 A MX2023000804 A MX 2023000804A MX 2023000804 A MX2023000804 A MX 2023000804A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- glucose
- promoting
- glucose transport
- promoting transport
- Prior art date
Links
- 230000001737 promoting effect Effects 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 230000006377 glucose transport Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000036314 physical performance Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un péptido natural promotor del transporte de glucosa que comprende un fragmento promotor del transporte de glucosa de una proteína seleccionada a partir de las SEQ ID NO s: 1 a 6, y una composición que comprende una pluralidad de péptidos promotores del transporte de glucosa. También se da a conocer el uso de los péptidos y las composiciones con el fin de mejorar el estado muscular en un mamífero, en especial para promover la recuperación muscular después del ejercicio o para mejorar el desempeño físico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15177018.7A EP3117831A1 (en) | 2015-07-16 | 2015-07-16 | Peptides for use in promoting transport of glucose into skeletal muscle |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000804A true MX2023000804A (es) | 2023-02-27 |
Family
ID=53719657
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000698A MX2018000698A (es) | 2015-07-16 | 2016-07-18 | Peptidos para usarse en la promocion del transporte de glucosa. |
MX2023000804A MX2023000804A (es) | 2015-07-16 | 2018-01-16 | Peptidos para usarse en la promocion del transporte de glucosa. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000698A MX2018000698A (es) | 2015-07-16 | 2016-07-18 | Peptidos para usarse en la promocion del transporte de glucosa. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190091282A1 (es) |
EP (3) | EP3117831A1 (es) |
JP (3) | JP2018523704A (es) |
KR (3) | KR20180033525A (es) |
CN (2) | CN114907464A (es) |
AU (3) | AU2016293136B2 (es) |
BR (1) | BR112018000656A2 (es) |
CA (1) | CA2992389A1 (es) |
MX (2) | MX2018000698A (es) |
WO (2) | WO2017009487A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
CN114650834A (zh) * | 2019-08-20 | 2022-06-21 | 努里塔斯有限公司 | 用于治疗肌肉萎缩的肽 |
WO2021108916A1 (en) * | 2019-12-06 | 2021-06-10 | Cooke Aquaculture Inc. | Peptides for regulating glucose |
EP4363435A1 (en) * | 2021-06-29 | 2024-05-08 | Gill, Thomas A. | Peptides for regulating glucose |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
ES2103366T3 (es) * | 1991-03-07 | 1997-09-16 | Novo Nordisk As | Hidrolizado proteico de guisante, metodo para su produccion y su utilizacion. |
US5516642A (en) * | 1992-11-16 | 1996-05-14 | Bristol-Myers Squibb Company | Polypeptides derived from major histocompatibility complex Class I antigen |
JP2673659B2 (ja) * | 1994-02-11 | 1997-11-05 | 株式会社ホーネンコーポレーション | ペプチド |
FR2751874B1 (fr) | 1996-08-02 | 1998-08-28 | Sederma Sa | Nouvelles compositions cosmetiques pour embellir et eclaircir la peau |
US6372717B1 (en) | 1996-08-23 | 2002-04-16 | Sederma S.A. | Synthetic peptides and their use in cosmetic or dermopharmaceutical compositions |
FR2758984B1 (fr) * | 1997-02-03 | 1999-04-16 | Serobiologiques Lab Sa | Complexe synergique actif et produit cosmetique et/ou pharmaceutique comprenant ce complexe |
FR2769502B1 (fr) | 1997-10-14 | 2000-04-14 | Sederma Sa | Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir du trefle (trifolium sp.) |
IT1313572B1 (it) | 1999-07-27 | 2002-09-09 | Enichem Spa | Procedimento per la preparazione di epossidi. |
JP2002348299A (ja) * | 2000-08-21 | 2002-12-04 | Takeda Chem Ind Ltd | Irap結合タンパク質 |
AR035860A1 (es) * | 2001-04-17 | 2004-07-21 | Femtolink Biotechnologies Llc | Metodos de deteccion por espectrometria de masa y cuantificacion de proteinas blanco especificas en muestras biologicas complejas |
US6936696B2 (en) * | 2001-09-17 | 2005-08-30 | Monsanto Company | Enhanced proteins and methods for their use |
CN1788017B (zh) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | 炎症状态下在血脑屏障中差异表达的核酸 |
SE0300795D0 (sv) | 2003-03-24 | 2003-03-24 | Isconova Ab | Composition comprising iscom particles and live micro-organisms |
WO2005023290A2 (en) | 2003-05-23 | 2005-03-17 | Pestka Biomedical Laboratories, Inc. | Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections |
WO2005048968A1 (en) | 2003-11-17 | 2005-06-02 | Sederma | Compositions containing mixtures of tetrapeptides and tripeptides |
US20050143303A1 (en) * | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
AU2006263332B2 (en) * | 2005-06-29 | 2012-02-23 | Hadasit Medical Research Services & Development Ltd. | Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes |
US8105572B2 (en) | 2007-05-18 | 2012-01-31 | New York University | Method of treating tuberculosis with interferons |
EP2039366A4 (en) * | 2006-04-21 | 2010-01-06 | Meiji Seika Kaisha | COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT |
US9034402B2 (en) * | 2007-04-16 | 2015-05-19 | Solae, Llc | Protein hydrolysate compositions having improved sensory characteristics and physical properties |
EP2050437A1 (en) | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
WO2011122937A1 (en) * | 2010-03-29 | 2011-10-06 | N.V. Nutricia | Pea protein peptides with anti helicobacter pylori activity |
ES2397890B1 (es) | 2011-03-25 | 2014-02-07 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas. |
EP2793605A1 (en) * | 2011-12-21 | 2014-10-29 | Laboratorios Ordesa, S.L | Process for obtaining rice protein hydrolysates useful in the prevention and/or treatment of obesity |
EP2897631A4 (en) * | 2012-08-31 | 2016-10-05 | Univ Virginia Patent Found | TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSIS |
US20170183386A1 (en) * | 2015-07-16 | 2017-06-29 | Nuritas Limited | Peptides, and uses thereof |
-
2015
- 2015-07-16 EP EP15177018.7A patent/EP3117831A1/en not_active Withdrawn
-
2016
- 2016-07-18 AU AU2016293136A patent/AU2016293136B2/en active Active
- 2016-07-18 EP EP21169260.3A patent/EP3932418A3/en active Pending
- 2016-07-18 CN CN202210535577.7A patent/CN114907464A/zh active Pending
- 2016-07-18 CA CA2992389A patent/CA2992389A1/en active Pending
- 2016-07-18 JP JP2018521715A patent/JP2018523704A/ja active Pending
- 2016-07-18 EP EP16751183.1A patent/EP3322432B1/en active Active
- 2016-07-18 KR KR1020187004162A patent/KR20180033525A/ko not_active IP Right Cessation
- 2016-07-18 KR KR1020227033939A patent/KR102551575B1/ko active IP Right Grant
- 2016-07-18 BR BR112018000656-4A patent/BR112018000656A2/pt active Search and Examination
- 2016-07-18 US US15/744,403 patent/US20190091282A1/en not_active Abandoned
- 2016-07-18 KR KR1020237022213A patent/KR20230107699A/ko not_active Application Discontinuation
- 2016-07-18 WO PCT/EP2016/067094 patent/WO2017009487A1/en active Application Filing
- 2016-07-18 WO PCT/EP2016/067098 patent/WO2017009491A1/en active Application Filing
- 2016-07-18 MX MX2018000698A patent/MX2018000698A/es unknown
- 2016-07-18 CN CN201680053425.6A patent/CN108135963A/zh active Pending
-
2018
- 2018-01-16 MX MX2023000804A patent/MX2023000804A/es unknown
-
2021
- 2021-01-05 US US17/141,778 patent/US20210196784A1/en active Pending
- 2021-05-03 AU AU2021202759A patent/AU2021202759B2/en active Active
- 2021-07-09 JP JP2021114272A patent/JP2021178829A/ja active Pending
-
2023
- 2023-03-01 AU AU2023201277A patent/AU2023201277A1/en active Pending
- 2023-07-14 JP JP2023115893A patent/JP2023126479A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016293136A1 (en) | 2018-02-01 |
AU2021202759B2 (en) | 2022-12-08 |
EP3322432B1 (en) | 2021-04-21 |
EP3932418A2 (en) | 2022-01-05 |
EP3117831A1 (en) | 2017-01-18 |
US20210196784A1 (en) | 2021-07-01 |
AU2016293136B2 (en) | 2021-02-04 |
CA2992389A1 (en) | 2017-01-19 |
KR20230107699A (ko) | 2023-07-17 |
US20190091282A1 (en) | 2019-03-28 |
AU2021202759A1 (en) | 2021-05-27 |
WO2017009491A1 (en) | 2017-01-19 |
JP2023126479A (ja) | 2023-09-07 |
KR102551575B1 (ko) | 2023-07-06 |
BR112018000656A2 (pt) | 2018-09-18 |
JP2021178829A (ja) | 2021-11-18 |
KR20180033525A (ko) | 2018-04-03 |
KR20220139421A (ko) | 2022-10-14 |
WO2017009487A1 (en) | 2017-01-19 |
EP3932418A3 (en) | 2022-04-20 |
MX2018000698A (es) | 2018-08-15 |
JP2018523704A (ja) | 2018-08-23 |
AU2023201277A1 (en) | 2023-04-06 |
CN114907464A (zh) | 2022-08-16 |
CN108135963A (zh) | 2018-06-08 |
EP3322432A1 (en) | 2018-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000804A (es) | Peptidos para usarse en la promocion del transporte de glucosa. | |
NZ737757A (en) | Peptide oligonucleotide conjugates | |
ZA201904723B (en) | Population-based immunogenic peptide identification platform | |
EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
NZ628625A (en) | Polypeptides binding to human complement c5 | |
MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2018000590A (es) | Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79). | |
EA201792245A1 (ru) | Биоконъюгаты и их применения | |
TN2012000372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
EA201990071A1 (ru) | Композиция пептидной вакцины | |
PE20220960A1 (es) | Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros | |
RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
EA201692279A1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
MX2019013982A (es) | Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21). | |
IN2015DN03206A (es) | ||
MY169230A (en) | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
EA201492068A1 (ru) | Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии | |
MY187334A (en) | Xylanase | |
EP2552462A4 (en) | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE | |
EA201691498A1 (ru) | Новая мишень для лечения и профилактики диабета | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. |